16 completed, 3 unknown, 1 withdrawn. 20 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 16, Unknown 3, Withdrawn 1 |
| Phase 2 | 5 | Completed 5 |
Follow Dry Eye Syndrome: new trials by email Literature Review of Dry Eye Syndrome trials Research Report on Dry Eye Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants ABBV-444 - Dry Eye Syndrome | Phase 3 | Completed | AbbVie | 40 | 2023-06-27 | 2024-10-15 |
| Comprehensive Study on Dry Eye and Ocular Surface Disease Prior and After Cataract Surgery The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod) - Dry Eye Disease, Dry Eye Syndrome | Phase 3 | Unknown | Fundación Oftalmológica Los Andes | 100 | 2021-01-15 | 2021-01-15 |
| Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients TJO-087, Cyclosporine ophthalmic solution 0.05% - Dry Eye Syndrome | Phase 3 | Unknown | Taejoon Pharmaceutical Co., Ltd. | 182 | 2020-06-19 | 2022-02-18 |
| Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment BRM421, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | BRIM Biotechnology Inc. | 220 | 2020-01-15 | 2026-05-01 |
| Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 610 | 2019-12-20 | 2022-01-19 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| Study of TOP1630 for Dry Eye Syndrome TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | Topivert Pharma Ltd | 202 | 2019-02-13 | 2019-08-07 |
| Study of SkQ1 as Treatment for Dry-eye Syndrome Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle) - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 452 | 2018-12-06 | 2022-01-19 |
| Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome HU007, Restasis, Moisview - Dry Eye Syndrome | Phase 3 | Completed | Huons Co., Ltd. | 209 | 2018-01-22 | 2020-05-08 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 RGN-259, Placebo - Dry Eye Syndrome | Phase 3 | Completed | ReGenTree, LLC | 601 | 2016-11-01 | 2026-10-21 |
| Study to Evaluate the Efficacy and Safety of CKD-350 Xenobella, Isotonic 0.3% Sodium Hyaluronate - Dry Eye Syndrome | Phase 3 | Unknown | Chong Kun Dang Pharmaceutical | 138 | 2016-05-01 | 2016-05-19 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 RGN-259, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | ReGenTree, LLC | 317 | 2015-09-01 | 2019-10-17 |
| Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease GENTEAL HA® Eye Drops (NOVARTIS, Switzerland), Physiological Sodium Chloride solution (0,9%) - Dry Eye Syndrome | Phase 3 | Withdrawn | Medical University of Vienna | 2014-12-01 | 2014-11-14 | |
| Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome T2762, Vismed® - Dry Eye Syndrome | Phase 3 | Completed | Laboratoires Thea | 105 | 2013-12-01 | 2017-08-24 |
| The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Methylprednisolone, Esomeprazole - Thyroid-associated Ophthalmopathy, Dry Eye Syndrome | Phase 3 | Completed | Medical University of Vienna | 18 | 2013-06-27 | 2020-02-20 |
| Efficacy and Safety of HE10 for Dry Eye Syndrome HE 10, Restasis - Dry Eye Syndrome | Phase 3 | Completed | Huons Co., Ltd. | 101 | 2013-05-01 | 2015-07-08 |
| Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome Rebamipide 2% ophthalmic suspension, Placebo (vehicle) - Dry Eye Syndrome | Phase 3 | Completed | Kubota Vision Inc. | 564 | 2012-06-01 | 2014-05-07 |
| Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle - Dry Eye Syndrome | Phase 3 | Completed | Alcon Research | 1936 | 2011-07-01 | 2013-07-08 |
| Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers Carboxymethylcellulose sodium, glycerin and polysorbate 80 - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | Optometric Technology Group Ltd | 40 | 2011-03-01 | 2013-11-28 |
| A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator - Dry Eye Syndrome | Phase 3 | Completed | Bausch & Lomb Incorporated | 840 | 2010-09-01 | 2020-09-04 |
Dry Eye Syndromes (20) · Keratoconjunctivitis (2) · Cataract (1) · Graves Ophthalmopathy (1) · Keratoconjunctivitis Sicca (1)
Eye Diseases (20) · Lacrimal Apparatus Diseases (20) · Conjunctival Diseases (3) · Conjunctivitis (3) · Corneal Diseases (3) · Keratitis (3) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Exophthalmos (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Goiter (1) · Graves Disease (1) · Hyperthyroidism (1)
Cyclosporins (2) · Visomitin (2) · thymosin beta(4) (2) · Cyclosporine (1) · Esomeprazole (1) · Hyaluronic Acid (1) · Methylprednisolone (1) · rebamipide (1)
Huons Co., Ltd. (2) · Medical University of Vienna (2) · Mitotech, SA (2) · ReGenTree, LLC (2) · AbbVie (1) · Alcon Research (1) · Aurinia Pharmaceuticals Inc. (1) · BRIM Biotechnology Inc. (1) · Bausch & Lomb Incorporated (1) · Chong Kun Dang Pharmaceutical (1) · Fundación Oftalmológica Los Andes (1) · Kubota Vision Inc. (1) · Laboratoires Thea (1) · Optometric Technology Group Ltd (1) · Taejoon Pharmaceutical Co., Ltd. (1)
United States (10) · South Korea (3) · Austria (2) · France (1) · United Kingdom (1)
Gail Torkildsen, MD (3) · Lawrence T Friedhoff, MD, PhD (2) · Blair Boehmer, MD (1) · Choun-Ki Joo (1) · Cristobal Loezar Hernandez, MD (1) · David Wirta, MD (1) · Eugene B McLaurin, MD (1) · Felipe Valenzuela Santana, MD (1) · Gerhard Garhoefer, MD (1) · Hyo Myung Kim, MD, PhD (1) · HyoMyung Kim, MD (1) · Juan Stoppel Ortiz, MD (1) · Luis Montecinos Buneder, MD (1)